BeiGene Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (10)

Latest Posts

About This Stock More About This Stock
Beijing-Based BeiGene Study Of PD-1 Antibody For Patients With Relapsed Or Refractory Hodgkin Lymphoma Underway
Article By: Lorimer Wilson
Sunday, April 23, 2017 1:47 AM EDT
Beijing-based BeiGene has dosed their first patient with refractory classical Hodgkin lymphoma — or cHL — in their Phase I PD-1 checkpoint trial of the drug BGB-A317 in a pivotal study which started less then four months ago.
In this article: BGNE Also: AZN, BMY, MRK, PFE, RHHBY, INCY, AGEN, TGTX
Read
Week In Review: Tianjin CanSino Closes $65 Million Round For Vaccine Portfolio
Article By: ChinaBio® Today
Saturday, April 22, 2017 3:40 PM EDT
Tianjin CanSino Biologics, a vaccine developer, raised $65 Million in its latest funding round. Currently, CanSino is testing four products in Phase I to III clinical trials, conducted in North America, Africa and China respectively.
In this article: MRK, PFE, CELG, IONS, BGNE
Read
Week In Review: Fosun Eyeing $4 Billion Bid For Germany's Stada Pharma
Article By: ChinaBio® Today
Saturday, March 11, 2017 1:52 PM EDT
Shanghai Fosun Pharma is said to be contemplating a bid for Germany's Stada Arzneimittel, a well established generic drug company.
In this article: BGNE, BYSI
Read
Week In Review: China's New Century Healthcare Plans Hong Kong IPO
Article By: ChinaBio® Today
Saturday, December 31, 2016 7:09 PM EDT
New Century Healthcare, which operates three pediatric clinics and recently acquired a women's hospital, all in Beijing, was approved to stage a $100 million IPO on the Hong Kong exchange. It's expected to take place in January 2017.
In this article: BGNE
Read
Week In Review: Beijing's Berry Genomics Valued At $619 Million In Reverse Merger
Article By: ChinaBio® Today
Saturday, December 24, 2016 4:36 PM EDT
Berry Genomics, a Beijing genetic testing company, will IPO via a reverse merger with Chengdu Tianxing Instrument & Meter (SHZ: 0710) at a valuation of $619 million on China's Shenzhen market.
In this article: SVA, BGNE
Read

PARTNER HEADLINES

Latest Tweets for $BGNE

No tweets yet!